盟科药业连亏4年，多位股东拟大笔减持

Core Insights - The company reported a total revenue of 142 million yuan for the last year, representing a year-on-year growth of 8.83%, but incurred a net loss of 242 million yuan, with a non-recurring net loss of 250 million yuan, although the loss has narrowed compared to the previous year [1] - The company's stock price has halved since its peak following its IPO, and it has experienced a 40% decline over the past five months [1] Group 1: Financial Performance - The company has recorded a quarterly trend of reduced losses, with non-recurring net losses of 63.3 million yuan in Q1, 80.1 million yuan in Q2, and 57.2 million yuan in Q3 of the last year [1] - The company attributed its losses to a decrease in idle funds used for purchasing trading financial assets, leading to a decline in fair value changes [1] Group 2: Product and Market Position - Currently, the company has only one product, Contizolam Tablets, which is in the commercialization stage and was approved for sale in China in June 2021 [2] - Sales revenue for Contizolam Tablets is projected to reach 130 million yuan in 2024, reflecting a year-on-year increase of 43.5%, but faces significant competition from multinational products like Pfizer's Linezolid and Merck's Tedizolid [2] Group 3: Research and Development Investment - The company invested 116 million yuan in R&D in the first half of the last year, which accounted for 173.83% of its revenue [3] - To alleviate financial pressure, the company planned to raise 1.03 billion yuan through a private placement to Nanjing Haiqing Pharmaceutical, but the plan was ultimately rejected by the largest shareholder, Genie Pharma [3] Group 4: Shareholder Actions - Several shareholders have announced plans to reduce their holdings, with Best Idea International Limited intending to sell up to 19.67 million shares, representing 3% of the total share capital [3] - Other shareholders, including JSR Limited and GP TMT Holdings Limited, also plan to reduce their stakes by up to 13.32 million shares and 6.34 million shares, respectively [3] Group 5: Stock Performance - The company was listed on the Sci-Tech Innovation Board on August 5, 2022, with an initial price of 8.16 yuan per share, reaching a peak of 14.20 yuan on its first trading day, but is currently trading below its IPO price [4]